Damien McDonald is the Chief Executive Officer of LivaNova.

Previously, Mr. McDonald served as Chief Operating Officer of LivaNova. Prior to that, he was Group Executive and Corporate Vice President at Danaher Corporation where he led a $1.5-billion group of dental consumables companies. Earlier in his tenure, he was Group President of Kerr where he and his team focused on building a strong research and development pipeline while improving operational performance utilizing the Danaher Business System. Additionally, Mr. McDonald previously led Zimmer’s spine division where he demonstrated his leadership skills, attracting a strong executive team that created a growth trajectory for the business unit. Earlier in his career, he worked with J&J’s Medical Device Franchises, including Ethicon, where he led marketing of the $2.5-billion medical device unit.

Mr. McDonald earned an MBA at the Institute for Management Development (IMD) in Lausanne, Switzerland, along with a Master of Science in International Economics from the University of Wales, U.K. He also holds a Bachelor of Economics degree and Bachelor of Pharmacy degree, both from the University of Queensland, Australia.

Stephanie Bolton is President, Europe, at LivaNova and is responsible for sales growth, team development and market penetration across the region. In 2011, Bolton joined Cyberonics, a LivaNova legacy company, where she moved into sales leadership roles and led the North Europe, UK and Ireland markets as a Vice President. Prior to that, Bolton spent more than eight years in the pharmaceutical industry at UCB, Otsuka Pharmaceuticals and Sankyo Pharma.

Bolton earned a Bachelor of Science degree in physiology with honors from Coventry University.

Paul Buckman has worked in the medical device industry for more than 30 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation, where he held several executive positions before becoming President of the cardiology division of Boston Scientific in January 2000.

From September 2013 to March 2017, Buckman served as CEO of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation. Additionally, from February 2012 to September 2013, Buckman was CEO of Sentreheart, Inc., a medical technology company focused on closure of various anatomic structures. 

Previously, Buckman served as CEO and Chairman of Pathway Medical Technologies, Inc., from September 2008 to February 2012; as CEO of Devax, Inc. from December 2006 to September 2008; and as President of the cardiology division of St. Jude Medical, Inc. from August 2004 to December 2006. 

Prior to joining LivaNova, Matthew Dodds served as Vice President, Strategic Planning at Johnson & Johnson (J&J) Medical Devices. Dodds joined J&J in 2015 after a 20-year career as an equity research analyst covering the Medical Supplies and Technology industry. He was the Sector Head of the Americas Health Care team at Citigroup.

Previously, Dodds was a Managing Director at SG Cowen and an Executive Director at UBS Warburg as the senior analyst covering Medical Supplies & Technology. Dodds also worked in the Equity Research departments at Kidder Peabody and PaineWebber.

Dodds earned a Bachelor of Science in industrial management from Carnegie Mellon University.

Marco Dolci joined LivaNova in 2017, coming from Danaher Corporation where he served as Vice President Danaher Business System-Dental Consumable Platform, earlier he was President Global Digital Dentistry and President Kerr EMEA and ASIA. Prior to his tenure at Danaher, Dolci served as President and CEO, EMEA for Hitachi Medical System Europe Holding AG. Earlier in his career, he worked in various positions at Eastman Kodak S.A. – Health Care Division, GE Healthcare and Philips Medical Systems. Dolci has more than 20 years of experience working in the healthcare and medical device industries.

Dolci earned a master’s degree in nuclear physics from University of Milan and an Executive MBA from Polytechnic University of Milan.

Trui Hebbelinck joined LivaNova in March 2019 as Chief Human Resources Officer and oversees global human resources. Hebbelinck’s career spans more than 20 years in healthcare, financial services and energy. She began as an HR manager in a private hospital, after which she joined General Electric, where she held various human resources positions over 15 years. During her five-year tenure at Shell, Hebbelinck served as a vice president of human resources in two different divisions within the company. Throughout her career, she has driven various talent programs, acquisition integrations and HR transformations, contributing to substantial growth for the companies where she worked.

Hebbelinck earned a Master of Science in Psychology from Ghent University in Belgium and a post-graduate degree in Business Management & Administration from the University of Leuven in Belgium.

Ryan Miller is Vice President, Strategy at LivaNova where he focuses on building the company’s capability in business processes and oversees its strategic planning process. Before joining LivaNova, Miller worked for Danaher where he held positions in global marketing, product management, business development and finance. He has expertise in working across complex matrixed organizations and delivering results through acquisitions, integration management and new product development.

Miller holds an MBA from the Wharton School of Business and a B.S. in accounting from the University of Southern California.

Dr. Olin joined Cyberonics in May 2009 as Vice President, Quality. In August 2009, he assumed additional responsibility for Clinical Affairs, and in April 2011, his responsibilities were expanded again to include Regulatory Affairs. With the 2015 merger between Cyberonics and Sorin, his responsibilities expanded to include corporate-wide responsibilities for the clinical, quality and regulatory affairs functions at LivaNova.

Prior to May 2009, Olin was employed at Zeltiq Aesthetics, Inc., a privately held medical technology company in the San Francisco area, where he served as Sr. Director, Quality Assurance. Between 1999 and 2007, Olin was employed at the LifeScan and Cordis companies of Johnson & Johnson, holding several positions of increasing responsibility in quality assurance, statistics and clinical data management. Olin began his career with Procter & Gamble in 1993 after obtaining his Ph.D. in statistics from Iowa State University.

He currently serves on the board of directors for the Medical Devices Innovation Consortium (MDIC) and as an industry representative on the Advisory Committee for The National Patient-Centered Clinical Research Network (PCORnet).

Alex Shvartsburg is the Chief Financial Officer of LivaNova.

From November 2020 to July 2021, Mr. Shvartsburg served as  the interim Chief Financial Officer of LivaNova. Prior to his appointment to the role, he led the LivaNova Corporate Financial Planning and Analysis group and was the International Region CFO. Before joining LivaNova in 2017, Mr. Shvartsburg was CFO and Chief Operating Officer of Caligor, a private equity-backed clinical services organization, where he was responsible for Finance, Operations, Human Resources and Information Technology functions. Before that, he held finance leadership roles including CFO of the Genetic Sciences division at Thermo Fisher Scientific, Senior Finance Director M&A at Life Technologies, and for over 20 years, Mr. Shvartsburg held a series of finance roles of increasing responsibility within Johnson & Johnson.

Mr. Shvartsburg earned a Bachelor of Science degree in Accounting from Drexel University and a Master of Business Administration from LaSalle University. He is a Certified Management Accountant.

Keyna Skeffington joined LivaNova in 2017, having worked in the medical device industry since 2004. She most recently served as Vice President of Legal – Corporate and Securities and Assistant Corporate Secretary at Medtronic, plc where she oversaw the legal support for corporate governance, compliance with the U.S. securities laws, mergers and acquisitions (including a $50-billion acquisition), strategic minority investments, indirect procurement, real estate and equity compensation. Prior to that role, she was the General Counsel for Medtronic’s Cardiac Surgery business. She is a frequent speaker on corporate governance, including at national conferences.

Earlier in her career, she was Partner at Faegre Baker Daniels LLP in its Corporate Finance Group and also practiced at Doherty, Rumble & Butler, P.A.

Skeffington earned her Juris Doctorate at Tulane University and Bachelor of Arts in International Relations and Russian at Mount Holyoke College.